U.S., Dec. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07277582) titled 'Phase 2/3 Study of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2)' on Dec. 02.
Brief Summary: The goal of this clinical trial is to learn whether the study drug THRV-1268 can safely and effectively shorten the QT interval in people diagnosed with Long QT Syndrome Type 2 (LQTS 2). The study will also learn about the safety and tolerability of THRV-1268 at different doses.
The main questions this study aims to answer are:
Does THRV-1268 reduce the QTc interval (a measure of the heart's electrical recovery time)?
What side effects or medical problems occur when participants take THRV-1268?
Which dose of THRV-1...